This study will evaluate the safety, efficacy and tolerability of fluvastatin extended release (80 mg once daily) in patients with metabolic...
Date First Received: April 21, 2008
Last Updated: April 22, 2008
Verified by: Novartis, April 2008
Clinical Trial Phase: Phase 4 | Start Date: September 2006
Overall Status: Completed
Estimated Enrollment: 878
Brief Summary
Official Title: “The Effect of Fluvastatin Treatment on the Lipid Profile in Patients With Metabolic Syndrome”
Condition Keyword(s):
Intervention(s):
This study will evaluate the safety, efficacy and tolerability of fluvastatin extended release (80 mg once daily) in patients with metabolic syndrome
Study Type: Interventional
Study Design: Treatment, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Study Primary Completion Date: October 2007
Intervention(s) in this Clinical Trial
- Drug: fluvastatin
- 80 mg once daily
Arms, Groups and Cohorts in this Clinical Trial
- Experimental: 1
Outcome Measures for this Clinical Trial
Primary Measures
- Change from baseline in total cholesterol levels at 6 weeks
- Time Frame: 6 weeks
Safety Issue?: No
- Time Frame: 6 weeks
Secondary Measures
- Adverse Events
- Time Frame: 6 weeks
Safety Issue?: Yes
- Time Frame: 6 weeks
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Male or female patients > 20 years of age
- Patients meeting at least three criteria for metabolic syndrome
- Triglycerides levels < 400 mg/dl and LDL cholesterol levels between 100 mg/dl and 190 mg/dl
- Written consent for participating in the study
- Patients who are able to communicate and able to follow all the requirements
Exclusion Criteria:
- Patients with severe renal disease or renal dysfunction
- Patients with chronic liver disease or liver function impairment
- Patients with inflammatory muscle dysfunction or findings of muscle problems
- Patients with severe cardiac failure
- Patients with findings of any cardiovascular event within the last 6 months Other protocol-defined inclusion/exclusion criteria may apply
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 20 Years
Maximum Age for this Clinical Trial: 90 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: Novartis
Additional Information
Information obtained from ClinicalTrials.gov on July 02, 2009
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00664742
Study ID Number: CXUO320BTR03
ClinicalTrials.gov Identifier: NCT00664742
Health Authority: Turkey: Ministry of Health
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.